KRAS and neoplasm: Variant allele frequency correlates with tumor load and PFS63% of therapy-naive patients experienced changes in their mutational profiles during chemotherapyPatients with mutations via blood-based liquid biopsy in BAP1, PBRM1, KRAS, or TP53 show a trend toward shorter PFS